UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 86

Sortiert nach

Screening for nonalcoholic fatty liver disease-when, who and how?

World journal of gastroenterology : WJG, 2021-09, Vol.27 (35), p.5803-5821

2021

Volltextzugriff (PDF)

Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study1

Journal of lipid research, 2017-01, Vol.58 (1), p.247-255

2017

Volltextzugriff (PDF)

Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis

PloS one, 2015-11, Vol.10 (11), p.e0142661-e0142661

2015

Volltextzugriff (PDF)

Non-invasive assessment of NAFLD as systemic disease-A machine learning perspective

PloS one, 2019-03, Vol.14 (3), p.e0214436-e0214436

2019

Volltextzugriff (PDF)

Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease

Cytokine & growth factor reviews, 2015-12, Vol.26 (6), p.625-635

2015

Volltextzugriff (PDF)

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

PloS one, 2022-06, Vol.17 (6), p.e0264741-e0264741

2022

Volltextzugriff (PDF)

Salt-Intake-Related Behavior Varies between Sexes and Is Strongly Associated with Daily Salt Consumption in Obese Patients at High Risk for MASLD

Nutrients, 2023-09, Vol.15 (18), p.3942

2023

Volltextzugriff (PDF)

Adaptation of iron transport and metabolism to acute high‐altitude hypoxia in mountaineers

Hepatology (Baltimore, Md.), 2013-12, Vol.58 (6), p.2153-2162

2013

Volltextzugriff (PDF)

Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature

BMC pharmacology & toxicology, 2018-10, Vol.19 (1), p.67-67, Article 67

2018

Volltextzugriff (PDF)

Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers

Journal of human genetics, 2018-05, Vol.63 (5), p.621-626

2018

Volltextzugriff (PDF)

Protein Kinase D2 drives chylomicron‐mediated lipid transport in the intestine and promotes obesity

EMBO molecular medicine, 2021-05, Vol.13 (5), p.e13548-n/a

2021

Volltextzugriff (PDF)

Host genetic variants in the pathogenesis of hepatitis C

Viruses, 2012-12, Vol.4 (12), p.3281-3302

2012

Volltextzugriff (PDF)

Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients

PloS one, 2018-12, Vol.13 (12), p.e0208225-e0208225

2018

Volltextzugriff (PDF)

An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy

Expert review of clinical pharmacology, 2021-03, Vol.14 (3), p.333-340

2021

Volltextzugriff (PDF)

Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4

Journal of clinical medicine, 2022-07, Vol.11 (15), p.4394

2022

Volltextzugriff (PDF)

Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events

JHEP reports, 2024-06, Vol.6 (6), p.101065-101065, Article 101065

2024

Volltextzugriff (PDF)

Emerging therapies for NASH - the future is now

Expert review of clinical pharmacology, 2017-05, Vol.10 (5), p.467-469

2017

Volltextzugriff (PDF)

Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment

Deutsches Ärzteblatt international, 2014-06, Vol.111 (26), p.447-452

2014

Volltextzugriff (PDF)

Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver

The Journal of immunology (1950), 2016-01, Vol.196 (1), p.97-105

2016

Volltextzugriff (PDF)

Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease

United European gastroenterology journal, 2018-12, Vol.6 (10), p.1496-1507

2018

Volltextzugriff (PDF)

Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study

Journal of lipid research, 2017-01, Vol.58 (1), p.247-255

2017

Volltextzugriff (PDF)

FRI-098 Feasibility of bedside ultrasonography of rectus femoris muscle for sarcopenia diagnosis in liver cirrhosis

Journal of hepatology, 2024-06, Vol.80, p.S223-S223

2024

Volltextzugriff (PDF)

FRI-103-YI Screening and assessing Sarcopenia in liver cirrhosis: feasibility and implications for clinical outcomes

Journal of hepatology, 2024-06, Vol.80, p.S224-S224

2024

Volltextzugriff (PDF)

WED-249 Improved risk stratification by combination of FIB-4 with FGF21 serum levels in steatotic liver disease

Journal of hepatology, 2024-06, Vol.80, p.S528-S529

2024

Volltextzugriff (PDF)

NAFLD patients scheduled for bariatric surgery present with a milder disease phenotype as compared to not morbidly obese NAFLD patients: analysis of a large real-world cohort

Journal of hepatology, 2022-07, Vol.77, p.S166

2022

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Aktive Filter

SpracheDeutsch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(82)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Screening for nonalcoholic fatty liver disease-when, who and how?

Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study1

Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis

Non-invasive assessment of NAFLD as systemic disease-A machine learning perspective

Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

Salt-Intake-Related Behavior Varies between Sexes and Is Strongly Associated with Daily Salt Consumption in Obese Patients at High Risk for MASLD

Adaptation of iron transport and metabolism to acute high‐altitude hypoxia in mountaineers

Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature

Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers

Protein Kinase D2 drives chylomicron‐mediated lipid transport in the intestine and promotes obesity

Host genetic variants in the pathogenesis of hepatitis C

Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients

An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy

Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4

Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events

Emerging therapies for NASH - the future is now

Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment

Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver

Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease

Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study

FRI-098 Feasibility of bedside ultrasonography of rectus femoris muscle for sarcopenia diagnosis in liver cirrhosis

FRI-103-YI Screening and assessing Sarcopenia in liver cirrhosis: feasibility and implications for clinical outcomes

WED-249 Improved risk stratification by combination of FIB-4 with FGF21 serum levels in steatotic liver disease

NAFLD patients scheduled for bariatric surgery present with a milder disease phenotype as compared to not morbidly obese NAFLD patients: analysis of a large real-world cohort

Aktive Filter

Suchergebnisse filtern